About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

NCT05833217·2 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Nicole Turk, BS
CONTACT
6508880144 nturk@stanford.edu

Lead

Stanford University

Age

18–80

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

Ages 18 to 80
BMI ≥ 25 kg/m2
not currently pregnant

You may not be if

Arm 2 (Adipose Tissue Biopsy) exclusions include
pregnancy
prior liposuction
recent change in weight (\> 2 kg in one month)
bleeding disorders
anticoagulant use
Arm 3 (healthy controls only) exclusions include patients with
major organ disease
diabetes
history of liposuction
bariatric surgery
eating disorders
psychiatric disorders
pregnancy or lactation
recent change in weight (over the past 12 weeks),
use of weight loss medication or oral steroids
hematocrit \< 33%
fasting glucose \>= 126 mg/dL
blood pressure \>160/100 mmHg

The record

StatusRecruiting

PhaseNo phase

Taking part55

StartedJun 2023

UpdatedDec 4, 2024

Conditions

Long COVID Insulin Resistance Insulin Sensitivity

Where2

Clinical and Translational Research Unit
Palo Alto, California, United States
Stanford Health
Palo Alto, California, United States